---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007861"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:22:33.857353+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences reports FY2022 net loss $68.2M; cash $276.6M; PALIZADE trial to start H1 2023

## Summary
- Cash, cash equivalents and marketable securities totaled $276.6M as of Dec 31, 2022, up from $208.4M in 2021.
- Net loss for FY2022 was $68.2M ($1.01 per share) vs $54.6M ($1.04 per share) in 2021.
- R&D expenses for FY2022 increased to $51.0M from $38.9M, driven by advancing zetomipzomib and KZR-261 programs.
- PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis to initiate in H1 2023; PORTOLA Phase 2a in autoimmune hepatitis ongoing.
- KZR-261 dose escalation currently enrolling Cohort 6; dose expansion study planned for H2 2023.

## SEC filing metadata
- accession: 0000950170-23-007861
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023007861/0000950170-23-007861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023007861/kzr-20230314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007861
- JSON: https://secwatch.observer/filing/0000950170-23-007861.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.